StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Aggregate of 7 sell-side ratings as of 2023-11-01. Stonvex does not endorse these ratings.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Next report date, year-over-year trend, and recent quarter history.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows BBLG's percentile within the scored universe — observational ranking, not a recommendation.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $1.27 | $1.27 | +0.00% | 0.0M |
| 05-18 | $1.30 | $1.25 | -3.85% | 0.0M |
| 05-19 | $1.33 | $1.26 | -5.26% | 0.0M |
| 05-20 | $1.25 | $1.23 | -1.60% | 0.0M |
| 05-21 | $1.23 | $1.24 | +0.41% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-08-12 | Q2 2021 2021-06-30 | Q1 2021 2021-03-31 | Annual 2020 2020-12-31 | Q3 2020 2020-09-30 |
|---|---|---|---|---|---|
Revenue | $0.00 | $1.07B | $1.07B | $1.07B | $1.07B |
Operating Income | Not available | $-412.81K | $-180.92K | $-825.01K | $-618.58K |
Net Income | Not available | $-491.90K | $-431.75K | $-1.82M | $-1.37M |
EPS (Diluted) | $-0.40 | $-0.32 | $-0.15 | Not available | Not available |
Total Assets | Not available | $4.44K | $71.17K | $0.00 | Not available |
Total Liabilities | Not available | $14.62M | $14.20M | $13.69M | $13.24M |
Cash & Equivalents | Not available | $4.44K | $71.17K | Not available | $2.46K |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available | Not available |
Shares Outstanding | Not available | 30.68M | 30.68M | 12.27M | 30.68M |
No sell-side coverage available for BBLG yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.